Kite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR-T Clinical Program in EU – StreetInsider.com
|
Kite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR–T Clinical Program in EU
StreetInsider.com Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that patients in the European Union (EU) are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1 … |
